Module 2: Obesity Management

Obesity as a Disease/Overview
Karli Burridge, PA-C, MMS, FOMA

  • Introduction to Obesity: Epidemiology, Burden, Impact on Cardiometabolic Health
  • Screening and Diagnosing Obesity
  • How to Initiate Discussion with Patients & Communication Strategies
  • Behavioral/motivational interviewing

Medical Management of Obesity
Donna H. Ryan, MD

  • Treating Obesity to the Standard of Care: Rationales, Principles, Comprehensive Considerations
  • Medicating the Patient with Obesity: Current and New Approaches to Help with Weight Loss and Weight Loss Maintenance

Metabolic Surgery
Christopher D. Still, DO 

  • Efficacy and Safety
  • Mechanisms of Action
  • Role in Reducing Cardiometabolic Risk Beyond Obesity (Diabetes & CVD risk)
  • Indications/Guidelines

Kenneth Cusi, MD; Christos S. Mantzoros, MD

  • Epidemiology, Pathophysiology, Mechanisms
  • Risk factors and Screening
  • Diagnosis (from non-invasive to invasive)
  • Therapeutic lifestyle management
  • Current Pharmacologic management
  • Emerging Pharmacotherapies & treatment targets

Target Audience

The Foundations of Cardiometabolic Health Certification Course is appropriate for clinicians from a full spectrum of clinical experience including Physicians, Physician Assistants, Nurse Practitioners, Registered Nurses, Pharmacists, Diabetologists, and Dietitians who are in any phase of training, or even experienced physicians who are looking to take a deeper dive into cardiometabolic health.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Define obesity as a treatable disease and incorporate practical approaches for its screening and diagnosis.
  • Summarize the efficacy and safety of lifestyle interventions and weight loss pharmacotherapy in the treatment of patients with obesity.
  • Discuss the efficacy and safety of metabolic surgery in the treatment of obesity, as well as improving cardiometabolic outcomes.
  • Review the burden, pathophysiology and impacts of NAFLD and NASH.
  • List current and emerging strategies for the screening, diagnosis, and treatment of NAFLD and NASH.
  • Develop comprehensive individualized treatment options for patients with obesity that promote and sustain weight loss.

Additional Information

Course summary
Available credit: 
  • 8.50 ABIM MOC and AMA PRA Category 1 Credit
  • 8.50 ACPE Pharmacy
  • 8.50 AMA PRA Category 1 Credit
  • 8.50 ANCC
  • 8.50 CDE
  • 8.50 Participation
Course opens: 
Course expires: 

Karli Burridge, PA-C, MMS, FOMA
Gaining Health, Enara Health

Ms. Burridge discloses the following:
Consultant: Gelesis, Bariatric Advantage, Currax, Novo Nordisk
Speaker: Currax, Vivus
Owner: Gaining Health

Donna Ryan, MD
Professor Emerita
Pennington Biomedical Research Center

Dr. Ryan discloses the following:
Advisory Boards/Consulting Fees: BI, Epitomee, Gila, IFA Celtic, Naturally Slim, Janssen, Novo Nordisk, Phenomix, United Health, ReDesign Health, Roman, Sanofi, Lilly, YSOP, Altimmune, Amgen, Zealand, PainScript
Speakers’ Bureau: Novo Nordisk
Stockholder/Stock Options: Xeno Bioscience, Epitommee, ReDesign Health, Scientific Intake, Calibrate, Roman Health
Other: DSMD for Rhythm Pharma; Steering Committee for Novo Nordisk

Christopher D. Still, DO, FACP, FTOS
Professor of Medicine
Department of Clinical Sciences
Geisinger Commonwealth School of Medicine
Medical Director, Center for Nutrition & Weight Management
Director, Geisinger Obesity Institute
Geisinger Health System

Dr. Still discloses the following:
Consulting Fee:  Ethicon Endo-Surgery, Medtronic, Novo Nordisk
Speakers Bureau:  Novo Nordisk
Contracted Research:  Ethicon Endo-Surgery, Novo Nordisk, Regeneron

Kenneth Cusi, MD, FACP, FACE 
Professor of Medicine
Chief, Division of Endocrinology, Diabetes and Metabolism
University of Florida, 
Gainesville, United States

Dr. Cusi discloses the following:
Research Support: Cirius, Echosens, Inventiva, Janssen, Nordic, Novartis, Novo Nordisk, Poxel, Target-NASH, Zydus
Consultant: Allergan, Amgen, AstraZeneca, Axcellia, 89Bio, BMS, Boehringer-Ingelheim, Coherus, Deuterex, Eli Lilly, Esperion, Fractyl, Ionis, Janssen, Genentech, Genfit, Gilead, Janssen, Madrigal, Merck, Novo Nordisk, Pfizer, Poxel, Prosciento, Sanofi-Aventis, Terns Pharma and Viscera Labs.

Christos S. Mantzoros, MD, DSc, PhD, h.c. mult.
Professor, Harvard Medical School  
Editor-in-chief, Metabolism, Clinical and Experimental 

Dr. Mantzoros discloses the following:
Consultant: Regeneron, Coherus, Novo Nordisk, Ansh, Lurios, Genfit, Intercept
Research Support: Merck, Coherus
Stockholder: Coherus

8.5 hours


In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Partners for Advancing Clinical Education designates this enduring material for a maximum of 8.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The maximum number of hours awarded for this Continuing Nursing Education activity is 8.5 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

Partners for Advancing Clinical Education designates this continuing education activity for 8.5 contact hour(s) (0.85 CEUs) of the Accreditation Council for Pharmacy Education.

This is an application-based activity. Universal Activity Numbers (UAN): JA4008073-9999-22-002-H01-P

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

This program offers 8.5 CPEUs for dieticians.


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.5 MOC points in the American Board of Internal Medicine's (ABIM) maintenance of certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.


Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS).

Partners for Advancing Clinical Education (PACE) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The PACE planners and others have nothing to disclose. The CMHC planners and others have nothing to disclose.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.  The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.  Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

During the period February 11, 2022 through June 24, 2023, participants must read the learning objectives and faculty disclosures, study the educational activity, obtain a score of 75% or better on the post-test, and complete the evaluation. Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us at

For questions about the accreditation of this activity, please visit

For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.

1) Complete this module post-test and evaluation.
2) Over the next 90 days, actively work to incorporate improvements in your clinical practice from these presentations.
3) Complete the follow-up survey from CMHC in approximately 90 days.

Available Credit

  • 8.50 ABIM MOC and AMA PRA Category 1 Credit
  • 8.50 ACPE Pharmacy
  • 8.50 AMA PRA Category 1 Credit
  • 8.50 ANCC
  • 8.50 CDE
  • 8.50 Participation
Please login or register to take this course.
Please login or register to take this course.

Required Hardware/software

A computer with an internet connection

Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser

Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.